摘要
目的:探讨基质金属蛋白酶-9(matrix metalloproteinase-9,MMP-9)与食管癌预后之间的关系。方法:采用酶联免疫吸附实验(ELISA)检测血清中MMP-9的含量。结果:MMP-9在淋巴结转移的食管癌患者血清中的含量为814.67±83.41μg/ml,在无淋巴结转移的食管癌患者血清中的含量为706.22±61.37μg/ml。MMP-9在淋巴结转移的食管癌患者血清中的含量显著高于无淋巴结转移的食管癌患者(P<0.05)。MMP-9在生存期>3年患者血清中的含量为716.22±54.18μg/ml,在生存期<3年患者血清中的含量为825.39±47.23μg/ml。MMP-9在生存期>3年患者血清中的含量显著低于生存期<3年的患者(P<0.05)。结论:MMP-9在食管癌的转移过程中发挥着重要作用,对判断预后有重要意义。
Objective： To study the relationship between matrix metalloproteinase-9（MMP-9） and prognosis of esophageal cancer. Methods ： The MMP-9 serum level was measured by ELISA. Results ： The MMP-9 serum level in esophageal cancer patients with lymphoma node metastasis was 814.67 ± 83.41μg/ml, and in esophageal cancer patients without lymphoma node metastasis was 706.22 ± 61.37μg/ ml. The MMP-9 level in the serum of patients with lymphoid node metastasis was higher than that of patients without lymphoid node metastasis significantly （ P 〈 0. 05 ）. The MMP-9 serum level in esophageal cancer patients survived 3 years was 716.22 ± 54.18, in patients died in 3 years was 825.39 ± 47.23. The MMP-9 serum level in esophageal cancer patients survived 3 years was much lower than that of patients died in 3 years. Conclusion ： MMP-9 is an useful prognostic factor for patients of esophageal cancer in clinic.
出处
《河南医学研究》
CAS
2005年第3期235-236,共2页
Henan Medical Research
